- Home
- VIVS vs BIAF Comparison
VIVS vs BIAF Comparison
Compare VIVS & BIAF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VIVS
- BIAF
- Stock Information
- Founded
- VIVS 2007
- BIAF 2014
- Country
- VIVS United States
- BIAF United States
- Employees
- VIVS N/A
- BIAF N/A
- Industry
- VIVS Biotechnology: Biological Products (No Diagnostic Substances)
- BIAF Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- VIVS Health Care
- BIAF Health Care
- Exchange
- VIVS Nasdaq
- BIAF Nasdaq
- Market Cap
- VIVS 8.1M
- BIAF 6.7M
- IPO Year
- VIVS N/A
- BIAF 2022
- Fundamental
- Price
- VIVS $2.25
- BIAF $1.59
- Analyst Decision
- VIVS
- BIAF Hold
- Analyst Count
- VIVS 0
- BIAF 1
- Target Price
- VIVS N/A
- BIAF N/A
- AVG Volume (30 Days)
- VIVS 1.4M
- BIAF 175.0K
- Earning Date
- VIVS 11-06-2025
- BIAF 11-14-2025
- Dividend Yield
- VIVS N/A
- BIAF N/A
- EPS Growth
- VIVS N/A
- BIAF N/A
- EPS
- VIVS N/A
- BIAF N/A
- Revenue
- VIVS $140,000.00
- BIAF $6,776,739.00
- Revenue This Year
- VIVS $42.38
- BIAF N/A
- Revenue Next Year
- VIVS $15.42
- BIAF $20.04
- P/E Ratio
- VIVS N/A
- BIAF N/A
- Revenue Growth
- VIVS 35.92
- BIAF N/A
- 52 Week Low
- VIVS $1.41
- BIAF $1.52
- 52 Week High
- VIVS $21.96
- BIAF $46.53
- Technical
- Relative Strength Index (RSI)
- VIVS 45.97
- BIAF 34.93
- Support Level
- VIVS $2.02
- BIAF $1.91
- Resistance Level
- VIVS $2.36
- BIAF $2.25
- Average True Range (ATR)
- VIVS 0.29
- BIAF 0.20
- MACD
- VIVS 0.01
- BIAF -0.06
- Stochastic Oscillator
- VIVS 23.64
- BIAF 6.54
About VIVS VivoSim Labs Inc. Common Stock
VivoSim Labs Inc formerly, Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases. It is now offering liver toxicology predictive screening and research services as well as working on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at all stages of drug development.
About BIAF bioAffinity Technologies Inc.
bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company's product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.